Abstract:Epilepsy Currents, Ahead of Print. Association Between Maternal Benzodiazepine or Z-Hypnotic Use in Early Pregnancy and the Risk of Stillbirth, Preterm Birth, and Small for Gestational Age: A Nationwide, Population-Based Cohort Study in Taiwan Meng L, Lin C, Lin Y, Huang S, Chen Y, Shang C, Wu C, Chen L, Chan KA, Hsiao F. Lancet Psychiatry. 2023;10(7):499-508. doi:10.1016/S2215-0366(23)00148-7.Background:Benzodiazepines and Z-hypnotics are commonly prescribed for anxiety and insomnia during pregnancy, but the evidence regarding potential adverse neonatal outcomes is insufficient because of poor control for confounding factors in previous studies. We therefore aimed to evaluate the association between the use of benzodiazepines or Z-hypnotics during early pregnancy and adverse neonatal outcomes (stillbirth, preterm birth, and small for gestational age).Methods:We did a nationwide, population-based cohort study in Taiwan using three data sources: Taiwan's National Birth Certificate Application database, the National Health Insurance database, and the Maternal and Child Health Database. The study cohort included all singleton pregnancies of females aged 15-50 years who gave birth between Jan 1, 2004, and Dec 31, 2018. Pregnancies without valid information were excluded. Benzodiazepine and Z-hypnotic use was defined as at least one benzodiazepine or Z-hypnotic prescription during early pregnancy (the first 20 weeks of pregnancy). The primary outcomes were stillbirth (fetal death at or after 20 weeks' gestation), preterm birth (<37 weeks' gestation), and small for gestational age (birthweight below the 10th percentile for gestational age by sex). Logistic regression models with propensity score fine stratification weighting were used to control for potential confounders and examine the association between benzodiazepines or Z-hypnotics use during early pregnancy and the risk of adverse neonatal outcomes. Odds ratios (ORs) and 95% CIs were reported. We used confounding by indication control analyses, a sibling control study, and a paternal negative control design to account for unmeasured confounders. The risk associated with exposure during late pregnancy was also assessed.Findings:Between Oct 7, 2021, and June 10, 2022, we analysed the study data. The cohort included 2 882 292 singleton pregnancies; of which, 75 655 (2·6%) of the mothers were dispensed one or more benzodiazepines or Z-hypnotics during early pregnancy. Women exposed during pregnancy were older (mean age at delivery was 31.0 years [SD 5.3] for exposed women vs 30.6 years [4.9] for unexposed women), had a higher prevalence of psychiatric disorders, and were more likely to have unhealthy lifestyle behaviours than unexposed women. Information about ethnicity was not available. Early pregnancy exposure was associated with adverse neonatal outcomes compared with non-exposure. The propensity score-weighted OR was 1.19 (95% CI 1.10-1.28) for stillbirth, 1.19 (1.16-1.23) for preterm birth, and 1.16 (1.13-1.19) for small for gestational age. After controlling for confounding by indication, there was no significant association between drug exposure and stillbirth risk; however, this attenuation was not observed for preterm birth and small for gestational age. In models with sibling controls that accounted for familial confounding and genetic factors, early exposure to benzodiazepines or Z-hypnotics was not associated with an increased risk of stillbirth and preterm birth, but it remained significantly associated with small for gestational age. The paternal negative control analyses with point estimates close to the null indicated no strong evidence of unmeasured confounding shared by the mother and the father. Substantially increased risks of stillbirth and preterm birth were observed for late pregnancy exposure.Interpretation:Benzodiazepine or Z-hypnotic use in early pregnancy is not associated with a substantial increase in the risk of stillbirth and preterm birth after accounting for unmeasured confounding factors. Clinicians should be aware of the increased risk of small for gestational age and caution should be taken when prescribing these medications during late pregnancy.

[Use of transthoracic 3D-echocardiography in congenital heart disease].

Immunofluorescent determination of the relative proportions of Streptococcus mutans in human dental plaque: a comparison with cultural techniques.

Microcalorimetric investigations of pharmaceutical complexes II. Drug-albumin interactions.

Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.

Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis

Birth outcomes following prenatal exposure to antidepressants

Neonatal outcomes after in utero exposure to antipsychotics: a systematic review and meta-analysis

Long-term neuropsychiatric morbidity in children exposed prenatally to preeclampsia

Effectiveness of extended postpartum inpatient monitoring for hypertensive disorders of pregnancy to reduce the risk of readmission for preeclampsia with severe features

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose

O2 and respiration in exercising human muscle. The regulation of oxidative phosphorylation in vivo.

Caution: Benzodiazepines in Pregnancy and Risk of Adverse Perinatal Outcomes

Genetic Insights Into Perinatal Outcomes of Maternal Antihypertensive Therapy

O22 MATERNAL AND FETAL OUTCOMES OF VARIOUS ANTIHYPERTENSIVE TREATMENT REGIMENS DURING PREGNANCY: INSIGHTS FROM THE CZECH NATIONAL REGISTRY 2012-2022

Intrapartum cardiotocography with simultaneous maternal heart rate registration improves neonatal outcome

Calculation of the resonant ionization of helium.

Immunohistochemical analysis of Bin1/Amphiphysin II in human tissues: Diverse sites of nuclear expression and losses in prostate cancer

Cardiovascular outcomes 50 years after antenatal exposure to betamethasone: Follow-up of a randomised double-blind, placebo-controlled trial

Beta-blockers and breastfeeding: a real-life prospective study

Short-term effects of antenatal betamethasone on fetal cardiovascular and circulation status: A quasi-experimental observational (before-after) study

Short-term outcomes in early term infants (born at 37 or 38 weeks): a retrospective investigation